Literature DB >> 25324577

Predictive Value of Class III D Cytological Diagnosis (Munich II, Low and Moderate Dysplasia) and Additional High-risk HPV Testing.

P Ziemke1.   

Abstract

The validity of cytological diagnostic procedures for the detection of pre- and early cervical cancer stages is limited due to biological conditions, the uncertainty of cell sampling, and the subjective nature of microscopic assessment. Particularly in class III D cases (Munich II) this can lead to a stigmatization of patients and uncertainty with regard to further clinical follow-up and therapy. Prior to carrying out additional investigations such as high-risk HPV testing or the examination of biomarkers, the positive predictive values of patients with a class III D cytological diagnosis need to be assessed in routine practice. To this end, all relevant data from patients from our practice classed as class III D (pap smears) between 2002 and 2008 (n = 1190; 38.2 % histological diagnosis = therapeutic endpoint) and their current HPV status were recorded. Cytology, histology, persistence, age and follow-up were recorded. The database was used for comparative statistical analysis. Overall, the positive predictive value of conventional pap smear for CIN 2+ was calculated to be 32.3 % (mean follow-up: 39.7 months). The following values were calculated for high-risk HPV testing: sensitivity 94.8 %, specificity 39 %, positive predictive value 42.8 %, negative predictive value 94 %. The additional information obtained from high-risk HPV testing resulted in a significantly better positive predictive value only in patients older than 40 years. However, there was no evidence for an individual risk stratification approach which would reduce uncertainty in the management of III D patients.

Entities:  

Keywords:  CIN; cervical carcinoma; cervical cytology; class III D; dysplasia

Year:  2012        PMID: 25324577      PMCID: PMC4168399          DOI: 10.1055/s-0032-1315089

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN: 0016-5751            Impact factor:   2.915


  20 in total

1.  The cellular morphology of carcinoma in situ and dysplasia or atypical hyperplasia of the uterine cervix.

Authors:  J W REAGAN; I L SEIDEMANN; Y SARACUSA
Journal:  Cancer       Date:  1953-03       Impact factor: 6.860

2.  Diagnostic accuracy of guided cervical biopsies: a prospective multicenter study comparing the histopathology of simultaneous biopsy and cone specimen.

Authors:  Christian Zuchna; Martina Hager; Barbara Tringler; Alexander Georgoulopoulos; Alexandra Ciresa-Koenig; Birgit Volgger; Andreas Widschwendter; Alfons Staudach
Journal:  Am J Obstet Gynecol       Date:  2010-07-14       Impact factor: 8.661

3.  The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials.

Authors:  Mark H Stoler; Michelle D Vichnin; Alex Ferenczy; Daron G Ferris; Gonzalo Perez; Jorma Paavonen; Elmar A Joura; Henning Djursing; Kristján Sigurdsson; Lucy Jefferson; Frances Alvarez; Heather L Sings; Shuang Lu; Margaret K James; Alfred Saah; Richard M Haupt
Journal:  Int J Cancer       Date:  2011-03-15       Impact factor: 7.396

Review 4.  Interpreting results in 2 x 2 tables: part 9 of a series on evaluation of scientific publications.

Authors:  Wilhelm Sauerbrei; Maria Blettner
Journal:  Dtsch Arztebl Int       Date:  2009-11-27       Impact factor: 5.594

5.  Cytology, histology, and colposcopy in the diagnosis of neoplastic non-invasive epithelial lesions of the cervix.

Authors:  G Gullotta; P A Margariti; C Rabitti; G Balsamo; D Valle; A Capelli; S Mancuso
Journal:  Eur J Gynaecol Oncol       Date:  1997       Impact factor: 0.196

Review 6.  Dysplasia and carcinoma in situ of the cervix.

Authors:  R H Kaufman
Journal:  Clin Obstet Gynecol       Date:  1967-12       Impact factor: 2.190

7.  Screening for cervical intraepithelial neoplasia grade 2/3: validity of cytologic study, cervicography, and human papillomavirus detection.

Authors:  A Schneider; D M Zahm; R Kirchmayr; V L Schneider
Journal:  Am J Obstet Gynecol       Date:  1996-05       Impact factor: 8.661

8.  Early detection of cervical carcinomas: finding an overall approach.

Authors:  Nicolas Wentzensen; Stefanie J Klug
Journal:  Dtsch Arztebl Int       Date:  2008-09-12       Impact factor: 5.594

9.  Management of low-grade CIN: follow-up or treatment?

Authors:  U Hording; J Junge; C Rygaard; F Lundvall
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1995-09       Impact factor: 2.435

10.  Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients.

Authors:  K-U Petry; S Menton; M Menton; F van Loenen-Frosch; H de Carvalho Gomes; B Holz; B Schopp; S Garbrecht-Buettner; P Davies; G Boehmer; E van den Akker; T Iftner
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

View more
  3 in total

Review 1.  [Indications for p16/Ki-67 in cervical cytology].

Authors:  P Ziemke; H Griesser
Journal:  Pathologe       Date:  2017-02       Impact factor: 1.011

2.  Aspects of Therapy for Cervical Cancer in Germany 2012 - Results from a Survey of German Gynaecological Hospitals.

Authors:  M Mangler; N Zech; A Schneider; C Köhler; S Marnitz
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-03       Impact factor: 2.915

3.  Cervical Cancer Screening: Defining the Need for Research.

Authors:  E Simoes; S Brucker; M W Beckmann; O Ortmann; C Albring; D Wallwiener
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-03       Impact factor: 2.915

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.